The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 28350896.
- Also identified by DOI 10.1093/cid/ciw824 and PMC identifier 5850447.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public health threat of antibacterial resistance. This article reports on the progress that the ARLG has made to date in fulfilling its mission. Since inception, the ARLG has received and reviewed >70 study proposals, initiated >30 studies, executed >300 agreements, included data from >7000 subjects, published >45 manuscripts, and provided opportunities for 26 mentees. Despite this substantial progress, there remains significant work to be accomplished. This article also describes the considerable challenges that lie ahead.
Medical subject headings
- Anti-Bacterial Agents
- Biomedical Research
- Drug Resistance, Bacterial
- Voluntary Health Agencies